BioCentury
ARTICLE | Finance

Wasting assets

December 21, 1998 8:00 AM UTC

By contrast, Corixa (CRXA) last week scooped up Anergen (ANRG) for $8.5 million in shares. ANRG, which had $2.4 million in cash at Sept. 30, has two products in the clinic and adds pieces to CRXA's budding autoimmune platform (see Cover Story).In addition, certain ANRG investors are ponying up $1.5 million in bridge loans to ease the deal through.

And Mobil and Exxon think oil prices are falling . . ...